Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis

1 Jan 2020

Abstract excerpt

The revolutionary immune checkpoint inhibitors (ICI) treatment has been a landmark of cancer therapy, with long-term survival benefit in advanced cancer patients reported.1 In another aspect, relatively low response rates and hyperprogression remain to be solved in immunotherapy.2 3 There have been some known biomarkers for the prediction of ICI efficacy, such as programmed death-ligand 1 expression, tumour...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33551066
DOI: 10.1136/esmoopen-2019-000614

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysisPMID 33551066Read ↗

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Immune checkpoints and cancer in the immunogenomics eraSemantic proximity Read ↗

Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read ↗

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a MatchmakerSemantic proximity Read ↗

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in CancerSemantic proximity Read ↗

Biomarkers of response to PD-1 pathway blockadeSemantic proximity Read ↗

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, other than Abscopal Effect: A Systematic ReviewSemantic proximity Read ↗

Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.Semantic proximity Read ↗

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade ResponseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.